Novo Nordisk and Gilead expand partnership

In a new phase IIb study, Novo Nordisk and Gilead plan to test a combination of three different drug treatments against nonalcoholic steatohepatitis (NASH), thereby extending the two companies' collaboration deal signed in 2019.

Photo: Novo Nordisk & Ritzau Scanpix/AP/Eric Risberg

Novo Nordisk and Gilead now declare themselves ready to expand their partnership agreement to tackle nonalcoholic steatohepatitis (NASH).

This extension will manifest in a phase IIb study involving 440 human test subjects.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs